Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -2.33% | -7.38% | -64.85% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 17.86 | 29.12 | 16.93 | 3.969 | 1.332 | 2.891 | - |
Enterprise Value (EV) 1 | 17.86 | 29.12 | 16.93 | 3.969 | 1.332 | 2.891 | 2.891 |
P/E ratio | -1.33 x | -2.25 x | -2.51 x | -0.19 x | -0.05 x | -0.42 x | -7.17 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 2.71 x | 2.93 x | 2.01 x | 0.28 x | 0.09 x | 0.21 x | 0.15 x |
EV / Revenue | 2.71 x | 2.93 x | 2.01 x | 0.28 x | 0.09 x | 0.21 x | 0.15 x |
EV / EBITDA | -1.91 x | -4.57 x | -1.94 x | -0.55 x | -0.18 x | -0.66 x | 4.13 x |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | 18.4 x | 2.36 x | 1.77 x | 0.38 x | 0.26 x | - | - |
Nbr of stocks (in thousands) | 22.8 | 34.1 | 36.7 | 58.2 | 187 | 1,152 | - |
Reference price 2 | 784.0 | 853.8 | 461.3 | 68.25 | 7.140 | 2.510 | 2.510 |
Announcement Date | 26/03/20 | 25/03/21 | 29/03/22 | 30/03/23 | 26/03/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 6.599 | 9.934 | 8.421 | 14.4 | 14.73 | 13.6 | 18.72 |
EBITDA 1 | -9.335 | -6.375 | -8.743 | -7.197 | -7.393 | -4.4 | 0.7 |
EBIT 1 | -9.4 | -6.426 | -8.862 | -7.68 | -7.596 | -4.495 | -0.395 |
Operating Margin | -142.45% | -64.69% | -105.24% | -53.32% | -51.58% | -33.05% | -2.11% |
Earnings before Tax (EBT) 1 | -9.652 | -11.03 | -5.824 | -10.61 | -9.64 | -5.42 | -0.395 |
Net income 1 | -10.49 | -11.04 | -6.559 | -16.26 | -16.7 | -5.42 | -0.395 |
Net margin | -158.92% | -111.12% | -77.89% | -112.92% | -113.38% | -39.85% | -2.11% |
EPS 2 | -588.0 | -379.8 | -183.8 | -353.5 | -138.6 | -5.950 | -0.3500 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 26/03/20 | 25/03/21 | 29/03/22 | 30/03/23 | 26/03/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 2.641 | 2.629 | 3.045 | 3.826 | 3.643 | 3.124 | 4.61 | 3.265 | 3.727 | 2.631 | 3.155 | 3.56 | 4.275 | 3.84 | 4.455 |
EBITDA 1 | -3.108 | -2.352 | -2.032 | -0.338 | -2.566 | -1.683 | -1.304 | -1.065 | -3.341 | -2.424 | -1 | -0.8 | -0.3 | -0.2 | 0.1 |
EBIT 1 | -3.195 | -2.382 | -2.152 | -0.457 | -2.689 | -1.734 | -1.355 | -1.116 | -3.391 | -2.436 | -1.12 | -0.735 | -0.22 | -0.84 | -0.29 |
Operating Margin | -120.98% | -90.6% | -70.67% | -11.94% | -73.81% | -55.51% | -29.39% | -34.18% | -90.98% | -92.59% | -35.5% | -20.65% | -5.15% | -21.88% | -6.51% |
Earnings before Tax (EBT) 1 | -0.159 | -0.111 | -2.155 | -0.136 | -8.206 | -1.739 | -2.036 | -1.757 | -4.108 | -3.09 | -1.12 | -0.735 | -0.22 | -0.84 | -0.29 |
Net income 1 | -0.894 | -0.111 | -2.155 | -5.793 | -8.206 | -1.739 | -4.032 | -1.757 | -9.169 | -3.594 | -1.12 | -0.735 | -0.22 | -0.84 | -0.29 |
Net margin | -33.85% | -4.22% | -70.77% | -151.41% | -225.25% | -55.67% | -87.46% | -53.81% | -246.02% | -136.6% | -35.5% | -20.65% | -5.15% | -21.88% | -6.51% |
EPS 2 | -36.75 | - | -49.00 | -122.5 | -151.5 | -29.75 | -44.45 | -12.95 | -46.55 | -5.250 | -1.225 | -0.7000 | -0.1750 | -0.8750 | -0.3500 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 29/03/22 | 12/05/22 | 11/08/22 | 14/11/22 | 30/03/23 | 11/05/23 | 10/08/23 | 09/11/23 | 26/03/24 | 09/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | 42.60 | 361.0 | 261.0 | 182.0 | 27.50 | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | 0.02 | 0.03 | 0.05 | 0.11 | 0.02 | 0.03 | 0.03 |
Capex / Sales | 0.29% | 0.26% | 0.62% | 0.78% | 0.13% | 0.22% | 0.16% |
Announcement Date | 26/03/20 | 25/03/21 | 29/03/22 | 30/03/23 | 26/03/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.85% | 2.89M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- NBY Stock
- Financials NovaBay Pharmaceuticals, Inc.